With hereditary angioedema (HAE), it takes courage to embrace a preventive approach. CINRYZE® (C1 esterase inhibitor [human]) is the first FDA-approved preventive treatment that can start at age 6.
Start with HAE attack prevention.
Not real patients.
With hereditary angioedema (HAE), it takes courage to embrace a preventive approach. CINRYZE® (C1 esterase inhibitor [human]) is the first FDA-approved preventive treatment that can start at age 6.
Start with HAE attack prevention.
Takeda Patient Support offers tailored support for CINRYZE.
We understand that living with hereditary angioedema looks different for everyone. We get to know you, understand who you are, and learn what's important to you - so we can provide the treatment support you need.
Our long-term commitment to the HAE community allows us to better understand and meet your unique needs.
After you and your physician choose a treatment path, Takeda Patient Support is here for you with a range of personalized services.
Takeda Patient Support is a product support program for people who have been prescribed CINRYZE. Our support specialists are here to address your questions and help get you the resources you need. Some of the resources we offer include:
To learn more about Takeda Patient Support visit: www.takedapatientsupport.com
*To be eligible, you must be enrolled in Takeda Patient Support and have commercial insurance. Other terms and conditions apply. Call us at 1‑866‑888‑0660 for more details.